Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization-Reference-Cited by-同舟云学术

Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization

Published:2006-07 Issue:2 Volume:48 Page:253-261
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Bakhai Ameet,Stone Gregg W.,Mahoney Elizabeth,Lavelle Tara A.,Shi Chunxue,Berezin Ronna H.,Lahue Betsy J.,Clark Mary Ann,Lacey Michael J.,Russell Mary E.,Ellis Stephen G.,Hermiller James B.,Cox David A.,Cohen David J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization;Morice;N Engl J Med,2002

2. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery;Moses;N Engl J Med,2003

3. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease;Stone;N Engl J Med,2004

4. Can we afford to eliminate restenosis? Can we afford not to?;Greenberg;J Am Coll Cardiol,2004

5. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses;Cohen;Circulation,2004

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: A Multicentre, Randomised, Sham-Controlled Trial;2023

2. Current status and future direction of metallic and polymeric materials for advanced vascular stents;Progress in Materials Science;2022-05

3. Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial;Value in Health;2019-12

4. Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial;EuroIntervention;2018-02

5. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention;JACC: Cardiovascular Interventions;2017-04